{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:18:08Z","timestamp":1790803088018,"version":"4.1.0"},"reference-count":50,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>In the United States, the proportion of Bordetella pertussis isolates lacking pertactin, a component of acellular pertussis vaccines, increased from 14% in 2010 to 85% in 2012. The impact on vaccine effectiveness (VE) is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We conducted 2 matched case-control evaluations in Vermont to assess VE of the 5-dose diphtheria, tetanus, and acellular pertussis vaccine (DTaP) series among 4- to 10-year-olds, and tetanus, diphtheria, and acellular pertussis vaccine (Tdap) among 11- to 19-year-olds. Cases reported during 2011 to 2013 were included. Three controls were matched to each case by medical home, and additionally by birth year for the Tdap evaluation. Vaccination history was obtained from medical records and parent interviews. Odds ratios (OR) were calculated by using conditional logistic regression; VE was estimated as (1-OR) \u00d7 100%. Pertactin status was determined for cases with available isolates.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Overall DTaP VE was 84% (95% confidence interval [CI] 58%\u201394%). VE within 12 months of dose 5 was 90% (95% CI 71%\u201397%), declining to 68% (95% CI 10%\u201388%) by 5\u20137 years post-vaccination. Overall Tdap VE was 70% (95% CI 54%\u201381%). Within 12 months of Tdap vaccination, VE was 76% (95% CI 60%\u201385%), declining to 56% (95% CI 16%\u201377%) by 2\u20134 years post-vaccination. Of cases with available isolates, &amp;gt;90% were pertactin-deficient.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Our DTaP and Tdap VE estimates remain similar to those found in other settings, despite high prevalence of pertactin deficiency in Vermont, suggesting these vaccines continue to be protective against reported pertussis disease.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2015-3973","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T12:22:21Z","timestamp":1460463741000},"source":"Crossref","is-referenced-by-count":66,"title":["Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis"],"prefix":"10.1542","volume":"137","author":[{"given":"Lucy","family":"Breakwell","sequence":"first","affiliation":[{"name":"Epidemic Intelligence Service, Scientific Education and Professional Development Program Office,"},{"name":"Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patsy","family":"Kelso","sequence":"additional","affiliation":[{"name":"Vermont Department of Health, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Finley","sequence":"additional","affiliation":[{"name":"Vermont Department of Health, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Vermont Department of Health, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant","family":"Goode","sequence":"additional","affiliation":[{"name":"Vermont Department of Health, Burlington, Vermont"},{"name":"Career Epidemiology Field Officer Program, Division of State and Local Readiness, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara K.","family":"Misegades","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"issue":"5","key":"2021120904413844600_B1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1542\/peds.68.5.650","article-title":"Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.","volume":"68","author":"Cody","year":"1981","journal-title":"Pediatrics"},{"issue":"3","key":"2021120904413844600_B2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1542\/peds.85.3.294","article-title":"Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy.","volume":"85","author":"Long","year":"1990","journal-title":"Pediatrics"},{"key":"2021120904413844600_B3","first-page":"1","article-title":"Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"2021120904413844600_B4","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Broder","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"34","key":"2021120904413844600_B5","first-page":"741","article-title":"National, state, and selected local area vaccination coverage among children aged 19\u201335 months - United States, 2013.","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"29","key":"2021120904413844600_B6","first-page":"625","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2013.","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"53","key":"2021120904413844600_B7","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases\u2014United States, 2012.","volume":"61","author":"Adams","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"2021120904413844600_B8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jpeds.2012.05.041","article-title":"California pertussis epidemic, 2010.","volume":"161","author":"Winter","year":"2012","journal-title":"J Pediatr"},{"issue":"28","key":"2021120904413844600_B9","first-page":"517","article-title":"Pertussis epidemic\u2014Washington, 2012.","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"48","key":"2021120904413844600_B10","first-page":"1129","article-title":"Pertussis epidemic\u2014California, 2014.","volume":"63","author":"Winter","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"2021120904413844600_B11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.2012.14939","article-title":"Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.","volume":"308","author":"Misegades","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"2021120904413844600_B12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1542\/peds.2014-3358","article-title":"Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.","volume":"135","author":"Acosta","year":"2015","journal-title":"Pediatrics"},{"issue":"9","key":"2021120904413844600_B13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/14760584.2014.935765","article-title":"Adult pertussis in the pre- and post-vaccine eras: lifelong vaccine-induced immunity?","volume":"13","author":"Cherry","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"2021120904413844600_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2567.1998.00401.x","article-title":"Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.","volume":"93","author":"Ryan","year":"1998","journal-title":"Immunology"},{"issue":"3","key":"2021120904413844600_B15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00431-001-0893-5","article-title":"Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.","volume":"161","author":"Lugauer","year":"2002","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2021120904413844600_B16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMc1209369","article-title":"Pertactin-negative variants of Bordetella pertussis in the United States.","volume":"368","author":"Queenan","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120904413844600_B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/CVI.00717-13","article-title":"Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.","volume":"21","author":"Pawloski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"2021120904413844600_B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu788","article-title":"Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.","volume":"60","author":"Martin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2021120904413844600_B19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1574-6968.2007.00833.x","article-title":"Autotransporter proteins: novel targets at the bacterial cell surface.","volume":"274","author":"Wells","year":"2007","journal-title":"FEMS Microbiol Lett"},{"issue":"7","key":"2021120904413844600_B20","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1128\/IAI.00188-10","article-title":"Pertactin is required for Bordetella species to resist neutrophil-mediated clearance.","volume":"78","author":"Inatsuka","year":"2010","journal-title":"Infect Immun"},{"key":"2021120904413844600_B21","first-page":"608","article-title":"Pertussis (whooping cough)","volume-title":"Red Book: 2015 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2015","edition":"30th ed."},{"issue":"46","key":"2021120904413844600_B22","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1016\/j.vaccine.2015.09.064","article-title":"Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.","volume":"33","author":"Safarchi","year":"2015","journal-title":"Vaccine"},{"key":"2021120904413844600_B23","unstructured":"Vermont Department of Health. Vermont Department of Health Pertussis Case Algorithm, 2012. Available at: http:\/\/healthvermont.gov\/prevent\/pertussis\/documents\/VermontPertussisAlgorithm25.pdf. Accessed May 1, 2015"},{"key":"2021120904413844600_B24","first-page":"1","article-title":"Case definitions for infectious conditions under public health surveillance.","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"2021120904413844600_B25","unstructured":"Vermont General Assembly. Immunization Registry Act of 1997. 18 VSA \u00a7 1129. Available at: http:\/\/legislature.vermont.gov\/statutes\/section\/18\/021\/011292007. Accessed October 22, 2013"},{"key":"2021120904413844600_B26","unstructured":"Vermont Department of Health. Vermont Immunization Manual, 2014. Available at: http:\/\/healthvermont.gov\/hc\/imm\/documents\/ProgramOverview.pdf. Accessed May 1, 2015"},{"issue":"11","key":"2021120904413844600_B27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJMoa1200850","article-title":"Waning protection after fifth dose of acellular pertussis vaccine in children.","volume":"367","author":"Klein","year":"2012","journal-title":"N Engl J Med"},{"key":"2021120904413844600_B28","doi-asserted-by":"crossref","first-page":"f4249","DOI":"10.1136\/bmj.f4249","article-title":"Effectiveness of pertussis vaccines for adolescents and adults: case-control study.","volume":"347","author":"Baxter","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"2021120904413844600_B29","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2012-1928","article-title":"Waning immunity to pertussis following 5 doses of DTaP.","volume":"131","author":"Tartof","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"2021120904413844600_B30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/cid\/ciu273","article-title":"Pertussis vaccine performance in an epidemic year-Oregon, 2012.","volume":"59","author":"Liko","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2021120904413844600_B31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/infdis\/jiu322","article-title":"Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.","volume":"210","author":"Koepke","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"2021120904413844600_B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.88.2.345","article-title":"Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells.","volume":"88","author":"Leininger","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"pt 5","key":"2021120904413844600_B33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1099\/mic.0.074690-0","article-title":"Antibody-mediated inhibition of Bordetella pertussis adenylate cyclase-haemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population.","volume":"160","author":"Hegerle","year":"2014","journal-title":"Microbiology"},{"issue":"49","key":"2021120904413844600_B34","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2014.09.068","article-title":"Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.","volume":"32","author":"Hegerle","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"2021120904413844600_B35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3201\/eid1903.121475","article-title":"Virulence of pertactin-negative Bordetella pertussis isolates from infants, France.","volume":"19","author":"Bodilis","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2021120904413844600_B36","doi-asserted-by":"crossref","first-page":"e18014","DOI":"10.1371\/journal.pone.0018014","article-title":"Studies on Prn variation in the mouse model and comparison with epidemiological data.","volume":"6","author":"van Gent","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"2021120904413844600_B37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1586\/14760584.2014.946016","article-title":"The baboon model of pertussis: effective use and lessons for pertussis vaccines.","volume":"13","author":"Warfel","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"2021120904413844600_B38","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JCM.01189-14","article-title":"Molecular epidemiology of the pertussis epidemic in Washington State in 2012.","volume":"52","author":"Bowden","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2021120904413844600_B39","doi-asserted-by":"crossref","first-page":"e31985","DOI":"10.1371\/journal.pone.0031985","article-title":"Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan.","volume":"7","author":"Otsuka","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2021120904413844600_B40","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1111\/j.1469-0691.2012.03925.x","article-title":"Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.","volume":"18","author":"Hegerle","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"33","key":"2021120904413844600_B41","doi-asserted-by":"crossref","first-page":"20881","DOI":"10.2807\/1560-7917.ES2014.19.33.20881","article-title":"Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.","volume":"19","author":"Zeddeman","year":"2014","journal-title":"Euro Surveill"},{"issue":"20","key":"2021120904413844600_B42","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0264-410X(98)00226-6","article-title":"A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.","volume":"16","author":"Cherry","year":"1998","journal-title":"Vaccine"},{"issue":"5","key":"2021120904413844600_B43","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.2012.6364","article-title":"Number and order of whole cell pertussis vaccines in infancy and disease protection.","volume":"308","author":"Sheridan","year":"2012","journal-title":"JAMA"},{"key":"2021120904413844600_B44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12916-015-0382-8","article-title":"Asymptomatic transmission and the resurgence of Bordetella pertussis.","volume":"13","author":"Althouse","year":"2015","journal-title":"BMC Med"},{"issue":"2","key":"2021120904413844600_B45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1073\/pnas.1314688110","article-title":"Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.","volume":"111","author":"Warfel","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2021120904413844600_B46","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"issue":"9","key":"2021120904413844600_B47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00431-010-1192-9","article-title":"Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children.","volume":"169","author":"von Linstow","year":"2010","journal-title":"Eur J Pediatr"},{"issue":"27\u201328","key":"2021120904413844600_B48","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1016\/j.vaccine.2004.03.046","article-title":"Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.","volume":"22","author":"Hviid","year":"2004","journal-title":"Vaccine"},{"issue":"11","key":"2021120904413844600_B49","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/cid\/ciu156","article-title":"Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010\u20132012.","volume":"58","author":"Barlow","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2021120904413844600_B50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/adc.88.8.684","article-title":"Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines.","volume":"88","author":"Liese","year":"2003","journal-title":"Arch Dis Child"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3973\/1060884\/peds_20153973.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3973\/1060884\/peds_20153973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:43:04Z","timestamp":1655487784000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/5\/e20153973\/52184\/Pertussis-Vaccine-Effectiveness-in-the-Setting-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,1]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-3973","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,1]]},"article-number":"e20153973"}}